PURPOSE To explore the feasibility of constructing tissue-engineered vascularised oral mucosa-like structures with rabbit ACVM-0.25% HLC-I scaffold and human gingival fibroblasts (HGFs), human gingival epithelial cells (HGECs) and vascular endothelial-like cells (VEC-like cells). METHOD Haematoxylin and Eosin (H&E) staining, immunohistochemical, immunofluorescence, 5-ethynyl-2'-deoxyuridine (EdU) staining and scanning electron microscope (SEM) were performed to detect the growth status of cells on the scaffold complex. After the scaffold complex implanted into nude mice for 28 days, tissues were harvested to observe the cell viability and morphology by the same method as above. Additionally, biomechanical experiments were used to assess the stability of composite scaffold. RESULTS Immunofluorescence and Immunohistochemistry showed positive expression of Vimentin, S100A4 and CK, and the induced VEC-like cells had the ability to form tubule-like structures. In vitro observation results showed that HGFs, HGECs and VEC-like had good compatibility with ACVM-0.25% HLC-I and could be layered and grow in the scaffold. After implanted, the mice had no immune rejection and no obvious scar repair on the body surface. The biomfechanical test results showed that the composite scaffold has strong stability. CONCLUSION The tissue-engineered vascularised complexes constructed by HGFs, HGECs, VEC-like cells and ACVM-0.25% HLC-I has good biocompatibility and considerable strength.

中文翻译：

---

在体外和体内研究基于ACVM-0.25％HLC-1支架的组织工程化血管化口腔粘膜样结构。

目的探讨用兔ACVM-0.25％HLC-1支架和人牙龈成纤维细胞（HGF），人牙龈上皮细胞（HGEC）和血管内皮样细胞（VEC-）构建组织工程化的血管化口腔粘膜样结构的可行性像细胞）。方法采用苏木精和曙红（H＆E）染色，免疫组化，免疫荧光，5-乙炔基-2'-脱氧尿苷（EdU）染色和扫描电子显微镜（SEM）检测支架复合物上细胞的生长状态。将支架复合物植入裸鼠28天后，通过与上述相同的方法收集组织以观察细胞活力和形态。另外，使用生物力学实验来评估复合支架的稳定性。结果免疫荧光和免疫组化显示波形蛋白，S100A4和CK的阳性表达，诱导的VEC样细胞具有形成小管样结构的能力。体外观察结果表明，HGF，HGEC和VEC样与ACVM-0.25％HLC-1具有良好的相容性，并且可以在支架中分层和生长。植入后，小鼠没有免疫排斥反应，并且在体表上没有明显的疤痕修复。生物力学测试结果表明，该复合支架具有很强的稳定性。结论由HGF，HGEC，VEC样细胞和ACVM-0.25％HLC-1构建的组织工程化血管复合物具有良好的生物相容性和相当的强度。体外观察结果表明，HGF，HGEC和VEC样与ACVM-0.25％HLC-1具有良好的相容性，并且可以在支架中分层和生长。植入后，小鼠没有免疫排斥反应，并且在体表上没有明显的疤痕修复。生物力学测试结果表明，该复合支架具有很强的稳定性。结论由HGF，HGEC，VEC样细胞和ACVM-0.25％HLC-1构建的组织工程化血管复合物具有良好的生物相容性和相当的强度。体外观察结果表明，HGF，HGEC和VEC样与ACVM-0.25％HLC-1具有良好的相容性，并且可以在支架中分层和生长。植入后，小鼠没有免疫排斥反应，并且在体表上没有明显的疤痕修复。生物力学测试结果表明，该复合支架具有很强的稳定性。结论由HGF，HGEC，VEC样细胞和ACVM-0.25％HLC-1构建的组织工程化血管复合物具有良好的生物相容性和相当的强度。